Women Embrace Promescent to close the Arousal Gap
Promescent, considered by many leading urologists to be the leading solution for male premature ejaculation, has dramatically increased sales to women across North America.
Newport Beach, CA (PRWEB) June 29, 2012
PROMESCENT, considered by many leading urologists to be the leading solution for male premature ejaculation, has dramatically increased sales to women across North America. Recently featured on Dr. Oz and CNN.com, PROMESCENT has proven its ability to cross-over from a successful treatment for a known medical condition to a lifestyle and satisfaction product embraced by both men and women. More importantly, the discussion of male and female sexual satisfaction related to the duration of intercourse has reached the mainstream media .
The average man takes approximately seven minutes to orgasm while the average woman takes approximately 16 minutes. This so-called “arousal gap” has been gaining more attention lately in mainstream media as evidenced by Laura Berman’s discussion about the topic on Dr. Oz’s “50 Shades of Grey”episode, which aired in late April. Men and women everywhere have had to resort to a variety of ineffective techniques to try and synchronize timing during sex. Such techniques often greatly reduce sexual pleasure for both men and women who simply want to have a satisfying and fulfilling sexual encounter together without interruption.
Prior to the Dr. Oz episode featuring PROMESCENT less than 1% of orders came from women. Now, it’s more than 35% and the percentage is rising. “Many men are still uncomfortable ordering a product associated with an issue that many still view as unusual and embarrassing,”says Jeff Abraham, CEO of Absorption Pharmaceuticals. “That’s starting to change as the arousal gap discussion is moving from the bedroom to the living room.” Even when the duration on the man’s part was sufficient to satisfy his partner, changing positions, slowing down, distracting himself mentally were all diminishing the event. That variable can now be taken out of the equation.
Many believe the topic premature ejaculation is at a similar stage now as erectile dysfunction was when Viagra© was first introduced in 1998. Most experts believe that the market demand for premature ejaculation products is potentially as large as the ED market, currently in excess of $5 Billion.
About Absorption Pharmaceuticals (AP), LLC.
Absorption Pharmaceuticals (AP), LLC., founded in 2008 and based in Newport Beach, CA, is the manufacturer of PROMESCENT. The FDA approved treatment under strict monograph guidelines was developed by Dr. Ronald Gilbert, Urologist, Founder and Chief Medical Officer of Absorption Pharmaceuticals. The lidocaine based topical anesthetic utilizes a patented, advanced, transcutaneous absorption technology. Since Promescent’s formal introduction in 2011, it has been enthusiastically embraced by leading experts in the field of sexual medicine and practicing urologists globally. PROMESCENT is currently sold in 42 countries and counting. AP is developing additional international distribution partnerships to continue dramatic sales growth in the coming months. The company’s mission is to be the leader in bringing awareness to the pervasive issue of premature ejaculation and providing the best, most effective treatment available. For general information or product inquires email questions to: info(at)promescent.com
# # #
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9655994.htm
